< 1 minute read
Dec. 20, 2021

Critical On-Target Toxicity with a VPS34 Kinase Inhibitor?

"compound 5"

oral selective VPS34 kinase inhibitor discontinued due to potential toxicity SBDD and SAR optimization Journal of Medicinal Chemistry Genentech Inc.

twitterlinkedinprintemail